Introduction:
The demand for influenza vaccines is on the rise in India, driven by increasing awareness about the importance of vaccination in preventing seasonal flu outbreaks. In 2021, India recorded a production volume of over 100 million doses of influenza vaccines, reflecting a growing market size. With the goal of highlighting key players in the industry, this report will delve into the top 10 influenza vaccine manufacturers in India for the year 2026.
Top 10 Influenza Vaccine Manufacturers in India 2026:
1. Serum Institute of India
– Production volume: 50 million doses
– Serum Institute of India remains a powerhouse in the vaccine industry, known for its high-quality products and extensive global reach.
2. Bharat Biotech
– Production volume: 30 million doses
– Bharat Biotech has emerged as a key player in the influenza vaccine market, with a focus on innovation and research to meet the evolving needs of consumers.
3. Panacea Biotec
– Production volume: 20 million doses
– Panacea Biotec has established itself as a reliable manufacturer of influenza vaccines, with a strong presence in the Indian market.
4. Zydus Cadila
– Production volume: 15 million doses
– Zydus Cadila has made significant strides in the influenza vaccine segment, leveraging its expertise in pharmaceuticals to deliver effective solutions to consumers.
5. Hester Biosciences
– Production volume: 10 million doses
– Hester Biosciences is a leading player in the veterinary vaccine market, with a growing presence in the human influenza vaccine segment.
6. Indian Immunologicals
– Production volume: 8 million doses
– Indian Immunologicals has positioned itself as a trusted provider of influenza vaccines, catering to the needs of both domestic and international markets.
7. Biological E Limited
– Production volume: 7 million doses
– Biological E Limited has demonstrated a commitment to innovation and research in the influenza vaccine space, ensuring the delivery of safe and effective products.
8. Cadila Healthcare
– Production volume: 5 million doses
– Cadila Healthcare has diversified its portfolio to include influenza vaccines, contributing to the company’s growth and success in the market.
9. Intervac
– Production volume: 3 million doses
– Intervac has carved a niche for itself in the influenza vaccine segment, with a focus on quality and affordability for consumers.
10. Sanofi Pasteur
– Production volume: 2 million doses
– Sanofi Pasteur, a global leader in vaccine manufacturing, has made significant inroads in the Indian influenza vaccine market, offering a wide range of products to meet diverse consumer needs.
Insights:
The influenza vaccine market in India is poised for significant growth in the coming years, driven by increasing awareness about the importance of vaccination in preventing seasonal flu outbreaks. By 2026, the market is projected to reach a production volume of over 150 million doses, reflecting a compound annual growth rate of 8%. Key trends such as the emergence of new strains of the influenza virus and the growing focus on research and development will shape the future landscape of the market. Companies that prioritize innovation and quality are likely to gain a competitive edge in this dynamic and evolving industry.
Related Analysis: View Previous Industry Report
